PT1818059E - Agente profilático ou terapêutico para o glaucoma - Google Patents
Agente profilático ou terapêutico para o glaucoma Download PDFInfo
- Publication number
- PT1818059E PT1818059E PT05819681T PT05819681T PT1818059E PT 1818059 E PT1818059 E PT 1818059E PT 05819681 T PT05819681 T PT 05819681T PT 05819681 T PT05819681 T PT 05819681T PT 1818059 E PT1818059 E PT 1818059E
- Authority
- PT
- Portugal
- Prior art keywords
- glaucoma
- therapeutic agent
- preventive
- salt
- preventing
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title 1
- 206010030043 Ocular hypertension Diseases 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000004410 intraocular pressure Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 230000004493 normal intraocular pressure Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63811804P | 2004-12-23 | 2004-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1818059E true PT1818059E (pt) | 2008-12-31 |
Family
ID=36601805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05819681T PT1818059E (pt) | 2004-12-23 | 2005-12-22 | Agente profilático ou terapêutico para o glaucoma |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1818059B1 (pt) |
| JP (1) | JP4099201B2 (pt) |
| KR (1) | KR101286813B1 (pt) |
| CN (1) | CN101087613B (pt) |
| AT (1) | ATE415972T1 (pt) |
| AU (1) | AU2005320085B2 (pt) |
| BR (1) | BRPI0519007A2 (pt) |
| CA (1) | CA2585372A1 (pt) |
| CY (1) | CY1108651T1 (pt) |
| DE (1) | DE602005011476D1 (pt) |
| DK (1) | DK1818059T3 (pt) |
| EA (1) | EA011085B1 (pt) |
| ES (1) | ES2317338T3 (pt) |
| MX (1) | MX2007007614A (pt) |
| MY (1) | MY138811A (pt) |
| NO (1) | NO20072187L (pt) |
| NZ (1) | NZ555137A (pt) |
| PL (1) | PL1818059T3 (pt) |
| PT (1) | PT1818059E (pt) |
| SI (1) | SI1818059T1 (pt) |
| TW (1) | TWI367098B (pt) |
| WO (1) | WO2006068208A1 (pt) |
| ZA (1) | ZA200704874B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101223475B (zh) * | 2005-07-14 | 2010-11-10 | 夏普株式会社 | 显示元件和使用该显示元件的电子设备 |
| EP2319514A4 (en) | 2008-07-25 | 2011-11-02 | Asahi Kasei Pharma Corp | STABLE AQUEOUS SOLUTION COMPOSITION COMPRISING A SULFONAMIDE COMPOUND |
| EP2671586B1 (en) * | 2011-02-04 | 2018-05-30 | Kowa Co., Ltd. | Drug therapy for preventing or treating glaucoma |
| EA026904B1 (ru) * | 2012-11-23 | 2017-05-31 | Игорь Михайлович Юхт | Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта) |
| EP3626245B1 (en) * | 2013-04-24 | 2021-05-05 | Kyushu University, National University Corporation | Therapeutic agent for eyeground disease |
| JP6236167B2 (ja) * | 2014-09-25 | 2017-11-22 | 興和株式会社 | 医薬品 |
| PT3199160T (pt) * | 2014-09-25 | 2020-04-08 | Kowa Co | Composição aquosa |
| TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
| CN107106571B (zh) | 2014-12-12 | 2021-02-05 | 兴和株式会社 | 水性组合物 |
| KR20160108121A (ko) | 2015-03-06 | 2016-09-19 | 코와 가부시키가이샤 | 수성 조성물 |
| JP2018118905A (ja) * | 2015-04-27 | 2018-08-02 | 恵 本庄 | 白内障術後合併症の予防治療剤 |
| CN106310285A (zh) * | 2015-06-15 | 2017-01-11 | 江苏吉贝尔药业股份有限公司 | 一种新的盐酸利舒地尔滴眼液及其制备方法 |
| JP6886322B2 (ja) * | 2016-03-25 | 2021-06-16 | 興和株式会社 | 眼科用組成物 |
| CN107164328A (zh) * | 2017-06-30 | 2017-09-15 | 太仓卡斯特姆新材料有限公司 | 一种高稳定性mcf‑7乳腺癌细胞的复苏方法 |
| WO2019124488A1 (ja) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 |
| JP2020193174A (ja) * | 2019-05-29 | 2020-12-03 | 興和株式会社 | 水性組成物 |
| CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9401108D0 (sv) * | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| DE19512639A1 (de) * | 1995-04-05 | 1996-10-10 | Merck Patent Gmbh | Benzonitrile und -fluoride |
| AU720326B2 (en) * | 1995-12-21 | 2000-05-25 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| JPH10310576A (ja) * | 1997-03-10 | 1998-11-24 | Hiroyoshi Hidaka | イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬 |
| KR100390612B1 (ko) * | 1997-04-25 | 2003-07-07 | 화이자 인코포레이티드 | 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법 |
| FR2777189B1 (fr) | 1998-04-09 | 2001-04-06 | Chauvin Lab Sa | Composition ophtalmique comprenant un beta-bloquant |
| EP1074545A4 (en) * | 1998-04-23 | 2001-08-22 | Hiroyoshi Hidaka | ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT |
| JP4212149B2 (ja) * | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
| US6673812B1 (en) | 1998-08-17 | 2004-01-06 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
| NZ510098A (en) * | 1998-10-22 | 2003-09-26 | Neurosearch As | Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel |
-
2005
- 2005-12-13 TW TW094144075A patent/TWI367098B/zh not_active IP Right Cessation
- 2005-12-14 MY MYPI20055888A patent/MY138811A/en unknown
- 2005-12-22 CA CA002585372A patent/CA2585372A1/en not_active Abandoned
- 2005-12-22 ES ES05819681T patent/ES2317338T3/es not_active Expired - Lifetime
- 2005-12-22 KR KR1020077012207A patent/KR101286813B1/ko not_active Expired - Lifetime
- 2005-12-22 AU AU2005320085A patent/AU2005320085B2/en not_active Ceased
- 2005-12-22 AT AT05819681T patent/ATE415972T1/de active
- 2005-12-22 BR BRPI0519007-0A patent/BRPI0519007A2/pt not_active IP Right Cessation
- 2005-12-22 JP JP2006549049A patent/JP4099201B2/ja not_active Expired - Lifetime
- 2005-12-22 EA EA200701134A patent/EA011085B1/ru not_active IP Right Cessation
- 2005-12-22 NZ NZ555137A patent/NZ555137A/en not_active IP Right Cessation
- 2005-12-22 PT PT05819681T patent/PT1818059E/pt unknown
- 2005-12-22 CN CN2005800444266A patent/CN101087613B/zh not_active Expired - Fee Related
- 2005-12-22 EP EP05819681A patent/EP1818059B1/en not_active Expired - Lifetime
- 2005-12-22 ZA ZA200704874A patent/ZA200704874B/xx unknown
- 2005-12-22 DE DE602005011476T patent/DE602005011476D1/de not_active Expired - Lifetime
- 2005-12-22 WO PCT/JP2005/023570 patent/WO2006068208A1/ja not_active Ceased
- 2005-12-22 SI SI200530540T patent/SI1818059T1/sl unknown
- 2005-12-22 PL PL05819681T patent/PL1818059T3/pl unknown
- 2005-12-22 DK DK05819681T patent/DK1818059T3/da active
- 2005-12-22 MX MX2007007614A patent/MX2007007614A/es active IP Right Grant
-
2007
- 2007-04-27 NO NO20072187A patent/NO20072187L/no not_active Application Discontinuation
-
2008
- 2008-12-11 CY CY20081101444T patent/CY1108651T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1108651T1 (el) | 2014-04-09 |
| EP1818059A1 (en) | 2007-08-15 |
| BRPI0519007A2 (pt) | 2008-12-23 |
| CA2585372A1 (en) | 2006-06-29 |
| KR101286813B1 (ko) | 2013-07-17 |
| AU2005320085B2 (en) | 2010-07-29 |
| EP1818059A4 (en) | 2007-12-26 |
| MX2007007614A (es) | 2007-08-15 |
| HK1113312A1 (zh) | 2008-10-03 |
| DK1818059T3 (da) | 2009-03-16 |
| NO20072187L (no) | 2007-07-13 |
| CN101087613A (zh) | 2007-12-12 |
| TWI367098B (en) | 2012-07-01 |
| EA011085B1 (ru) | 2008-12-30 |
| TW200628160A (en) | 2006-08-16 |
| ATE415972T1 (de) | 2008-12-15 |
| JP4099201B2 (ja) | 2008-06-11 |
| SI1818059T1 (sl) | 2009-04-30 |
| ES2317338T3 (es) | 2009-04-16 |
| NZ555137A (en) | 2009-10-30 |
| WO2006068208A1 (ja) | 2006-06-29 |
| ZA200704874B (en) | 2008-08-27 |
| KR20070090897A (ko) | 2007-09-06 |
| PL1818059T3 (pl) | 2009-05-29 |
| AU2005320085A1 (en) | 2006-06-29 |
| EP1818059B1 (en) | 2008-12-03 |
| DE602005011476D1 (de) | 2009-01-15 |
| MY138811A (en) | 2009-07-31 |
| EA200701134A1 (ru) | 2007-10-26 |
| JPWO2006068208A1 (ja) | 2008-06-12 |
| CN101087613B (zh) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072187L (no) | Preventivt eller terapeutisk middel for glaucom | |
| WO2007076360A8 (en) | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions | |
| EP1497420A4 (en) | AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES | |
| WO2006066103A3 (en) | Ophthalmic implant for treatment of glaucoma | |
| WO2002080811A3 (en) | Glaucoma stent and methods thereof for glaucoma treatment | |
| WO2003005941A3 (de) | Insert zur behandlung des trockenen auges | |
| AU5198199A (en) | Preventives/remedies for glaucoma | |
| WO2002098350A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
| WO2007126364A3 (en) | Use of antisecretory factors for treating intraocular hypertension | |
| WO2004069181A3 (en) | Composition for the treatment of intraocular pressure | |
| WO2007076367A3 (en) | Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma | |
| WO2005027884A3 (en) | Stabilized ocular solutions | |
| WO2007127711A3 (en) | Abnormal cannabidiols as agents for lowering intraocular pressure | |
| ZA200607988B (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| WO2007014033A3 (en) | Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure | |
| MX2008015976A (es) | Tratamiento topico para enfermedades de superficie ocular. | |
| WO2004019874A3 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| EP1482922A4 (en) | AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS | |
| EP1396264A4 (en) | MEANS TO REDUCE FAULTS IN THE EYE CONTROL FUNCTION | |
| MXPA04001255A (es) | Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. | |
| TW200806284A (en) | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma | |
| WO2003101379A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
| WO2006061525A3 (fr) | Compositions pour le traitement des pathologies oculaires de surface | |
| WO2002060339A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| HK1075466A (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |